David Larson
Analyst, BTIG
Replay available
Omnicell, Inc. (NASDAQ: OMCL) Q1 2025 earnings conference call, held 2025-05-06. Replay captured from the company's public earnings webcast.

Analyst, BTIG
Analyst, Craig Hallam
Senior Vice President, Investor Relations
Analyst, Piper Sandler
Executive Vice President and Chief Operating Officer
Executive Vice President and Chief Financial Officer
Chairman, President, CEO and Founder
Analyst, Benchmark
Analyst, Bank of America
Analyst, Wells Fargo
Analyst, Freedom Capital Markets
and I will be your conference operator today. At this time, I would like to welcome everyone to the OmniCell first quarter 2025 financial results conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you. I would now like to turn the call over to Kathleen Nemeth, Senior Vice President, Investor Relations. Please go ahead. Good morning and welcome to the Omnicell first quarter 2025 financial results conference call. On the call with me today are Randall Lipps, Omnicell Chairman, President, CEO, and Founder, Nandi Njoku, Executive Vice President and Chief Operating Officer, and Chacha Eta, Executive Vice President and Chief Financial Officer. This call will contain certain forward-looking statements, including statements related to financial projections or performance, or other statements regarding OmniCell's plans, strategy, objectives, goals, vision, expectations, planned investments, opportunities, expense mitigation, products, services or solution, driving toward a recurring revenue model, navigating the current macroeconomic environment, the impact of or ability to mitigate the impact of tariffs or market or company outlook that are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. For a more detailed description of the risks that impact these forward-looking statements, Please refer to the information in our press release issued today in the OmniCell Annual Report on Form 10-K fil...